1. Home
  2. TG vs IPHA Comparison

TG vs IPHA Comparison

Compare TG & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tredegar Corporation

TG

Tredegar Corporation

HOLD

Current Price

$7.97

Market Cap

353.3M

Sector

Industrials

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$2.01

Market Cap

131.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TG
IPHA
Founded
1988
1999
Country
United States
France
Employees
N/A
163
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
353.3M
131.4M
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
TG
IPHA
Price
$7.97
$2.01
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.75
AVG Volume (30 Days)
175.9K
118.2K
Earning Date
05-08-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
151.06
N/A
EPS
0.17
N/A
Revenue
$800,821,000.00
N/A
Revenue This Year
N/A
$180.36
Revenue Next Year
N/A
N/A
P/E Ratio
$47.91
N/A
Revenue Growth
8.29
N/A
52 Week Low
$6.25
$1.18
52 Week High
$10.53
$2.63

Technical Indicators

Market Signals
Indicator
TG
IPHA
Relative Strength Index (RSI) 35.25 63.24
Support Level $7.30 $1.69
Resistance Level $8.04 $2.16
Average True Range (ATR) 0.57 0.16
MACD -0.25 0.06
Stochastic Oscillator 2.30 47.05

Price Performance

Historical Comparison
TG
IPHA

About TG Tredegar Corporation

Tredegar Corp is engaged in the manufacture of aluminum extrusions and polyethylene and polypropylene plastic films. It produces surface protection films, packaging films and films for other markets. The company continues to have two reportable segments: Aluminum Extrusions and High Performance Films. The majority of the revenue is derived form the Aluminum Extrusions segment which produces high-quality, soft and medium strength alloyed aluminum extrusions, custom fabricated and finished, for the building and construction, automotive and transportation, consumer durables goods, machinery and equipment, electrical and renewable energy, and distribution markets.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: